Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

August 14, 2024

https://www.globenewswire.com/news-release/2024/08/13/2929090/0/en/Abeona-Therapeutics-Announces-Favorable-Medicare-Reimbursement-Decisions-for-Pz-cel.html

CLEVELAND, Ohio, Aug. 13, 2024 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq:ABEO) today announced that the Centers for Medicare and Medicaid Services (CMS) has granted a product-specific procedure code ICD-10-PCS (International Classification of Diseases, 10th Revision, Procedure Coding System) for prademagene zamikeracel (pz-cel), Abeona’s investigational autologous cell-based gene therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). If pz-cel receives U.S. marketing approval, this code will allow for efficient and accurate documentation, billing, and analysis of inpatient hospital procedures using pz-cel. The code will go into effect on October 1, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.